SCHEMBL5832256

SCHEMBL5832256

COc1cccc(-c2ccc(-c3nc4ccccc4o3)cc2OC)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.65
MAPT P10636 8/20 0.51
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 6/20 0.51
PTGS2 P35354 2/20 0.51
ALOX5 P09917 1/20 0.50
HPSE Q9Y251 1/20 0.47
POLB P06746 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
TP53 P04637 3/20 0.46
HPGD P15428 5/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 4/20 0.45
TSHR P16473 3/20 0.45
USP2 O75604 2/20 0.45
P2RY14 Q15391 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832825 0.90 NPC1 (0.64) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL5831907 0.88 NPC1 (0.65) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL12956189 0.85 NPC1 (0.79) NPC1MAPTKDM4EALDH1A1PTGS2
Hydrochloric Acid SCHEMBL5831703 0.84 NPC1 (0.65) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL5832540 0.80 NPC1 (0.55) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL28436509 0.80 NPC1 (1.00) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL5832164 0.80 NPC1 (0.62) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL5831870 0.80 NPC1 (0.62) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL5832552 0.79 NPC1 (0.59) NPC1MAPTKDM4EALDH1A1PTGS2
SCHEMBL5832587 0.79 NPC1 (0.61) NPC1MAPTKDM4EALDH1A1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885MAPT 2892/4885KDM4E 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.